Opioid Use Disorder

FDA Approves Once-Monthly Buprenorphine Injection for Opioid Use Disorder

FDA Approves Once-Monthly Buprenorphine Injection for Opioid Use Disorder

By

In a press release issued November 30, 2017, the US Food and Drug Administration announced it has approved Sublocade, a once-monthly buprenorphine injection for moderate to severe opioid use disorder.

Immediate Access to Opioid Agonist Treatment Is Cost-Effective, Beneficial

Immediate Access to Opioid Agonist Treatment Is Cost-Effective, Beneficial

Immediate access to opioid agonist treatment for patients presenting with opioid use disorder may provide greater health benefits at less cost than observed standard of care.

Motivational Interview Intervention Reduces Opioid Overdose

Motivational Interview Intervention Reduces Opioid Overdose

By

A motivational interviewing intervention delivered by trained counselors reduced the rate of opioid overdoses in participants with opioid use disorder.

Collaborative Care Superior to Standard Care for Opioid Use Disorder

Collaborative Care Superior to Standard Care for Opioid Use Disorder

By

Patients with opioid and/or alcohol use disorders have better treatment access and greater rates of alcohol and drug abstinence at 6 months with collaborative care vs standard addiction care.

Tramadol Effective on Opioid Withdrawal Symptoms

Tramadol Effective on Opioid Withdrawal Symptoms

By

The extended-release formulation of tramadol was shown to be as effective as buprenorphine and more effective than clonidine for treating symptoms of opioid withdrawal.

Buprenorphine Injections Effective on Opioid-Associated Euphoria and Withdrawal

Buprenorphine Injections Effective on Opioid-Associated Euphoria and Withdrawal

By

Once-weekly subcutaneous buprenorphine injections block the euphoric effects of opioids and suppress opioid withdrawal in patients with opioid use disorder.

Buprenorphine and Naltrexone Underprescribed for Youth With Opioid Use Disorder

Buprenorphine and Naltrexone Underprescribed for Youth With Opioid Use Disorder

By

Early pharmacologic intervention for opioid use disorder after diagnosis is crucial to prevent relapse and overdose in adolescents and young adults.

Discrepancies in Subjective vs Objective Sleep in Patients Receiving Buprenorphine for Opioid Use Disorder

Discrepancies in Subjective vs Objective Sleep in Patients Receiving Buprenorphine for Opioid Use Disorder

By

Patients receiving buprenorphine maintenance therapy for their opioid use disorder may have impaired sleep, despite their reports of improved quality and duration of sleep.

High Mortality In Patients With Opioid Use Disorder In General Healthcare Setting

High Mortality In Patients With Opioid Use Disorder In General Healthcare Setting

By

A recent study found high rates of mortality and morbidity in patients with opioid use disorder in a large healthcare system.

The Consequences of Limiting Physician Capacity to Rx Buprenorphine for Opioid Use Disorder

The Consequences of Limiting Physician Capacity to Rx Buprenorphine for Opioid Use Disorder

By

The researchers found that novice prescribers cited insufficient access to substance abuse counseling for patients, as well as insufficient access to more experienced prescribers, as reasons for not treating more patients.

Rates of Opioid Agonist Therapy Prescriptions for Medicare Patients Reflect Treatment Gap

Rates of Opioid Agonist Therapy Prescriptions for Medicare Patients Reflect Treatment Gap

By

A small fraction of prescriptions for Medicare patients are for opioid agonist therapy, despite higher rates of abuse.

Sign Up for Free e-Newsletters